The anti-obesity antibody

Written by Tristan Free (Digital Editor)

black rat on white background

As the obesity and COVID-19 pandemics collide, new research presents a possible vehicle to advance obesity treatment. A new study has revealed an antibody mimetic of fibroblast growth factor 21 (FGF21) that is safe and effective in reducing the weight of obese patients in a recent clinical study. Led by Puneet Arora (Principia Biopharma, CA, USA), the team first conducted trials in non-human primates before moving on to a small clinical trial to test their obesity treatment in a human model. The task of finding new resolutions to the obesity pandemic has been a key focus for researchers in the...

To view this content, please register now for access

Join our member community for FREE to access a collection of journal and online-only features, including:

  • Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
  • The latest news and journal updates delivered straight to your inbox when you want it
  • Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
  • Priority registration to webinars, panel discussions and events
  • Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!